ARTICLE | Clinical News
Boston Life Sciences completes Phase III
March 15, 2000 8:00 AM UTC
BLSI completed enrollment of a 160-patient Phase III trial of Altropane to diagnose early Parkinson's disease. Altropane is a radioimaging agent binding to dopamine transporter sites in the brain. ...